# AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Source: https://onco.cc/trials/nct07218809/  
OnCo record `nct07218809` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing AZD5335 in ovarian cancer, now recruiting.

## Summary

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer is a phase 3 interventional study registered as NCT07218809, led by AstraZeneca with European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation and Ventana Medical Systems, and recruiting on the registry. Official title: A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01). Planned enrolment is 1100 participants (estimated). The study started in 2025-12-29 and primary completion is expected in 2028-11-17. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: TREVI-OC-01
- Tags: ctgov-ingest
- Registry id: NCT07218809
- Phase: 3
- Setting: A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
- Sponsor: AstraZeneca
- Enrolled: 1100

## Sources

- ClinicalTrials.gov NCT07218809: https://clinicaltrials.gov/study/NCT07218809

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [AZD5335](https://onco.cc/drugs/azd5335/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07218809.json